title: Comments about the prospective randomized trial by Aoyama et al.
authors.forename: Roy A
authors.initials: RA
authors.lastname: Patchell
authors.forename: William F
authors.initials: WF
authors.lastname: Regine
authors.forename: Markus
authors.initials: M
authors.lastname: Renschler
authors.forename: Jay S
authors.initials: JS
authors.lastname: Loeffler
authors.forename: Raymond
authors.initials: R
authors.lastname: Sawaya
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Chin
authors.forename: David W
authors.initials: DW
authors.lastname: Andrews
mesh_terms: D024221:Antineoplastic Protocols / Q000592:standards; D001932:Brain Neoplasms / Q000503:physiopathology / Q000532:radiotherapy* / Q000601:surgery; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D006801:Humans; D009362:Neoplasm Metastasis / Q000517:prevention & control* / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000503:physiopathology / Q000532:radiotherapy* / Q000601:surgery; D011878:Radiotherapy / Q000009:adverse effects / Q000592:standards*; D016032:Randomized Controlled Trials as Topic / Q000592:standards* / Q000706:statistics & numerical data; D012107:Research Design; D015996:Survival Rate